Fibroblast Growth Factor-23, Cardiovascular Prognosis, and Benefit of Angiotensin-Converting Enzyme Inhibition in Stable Ischemic Heart Disease

OBJECTIVES: This study sought to test 2 hypotheses: 1) fibroblast growth factor (FGF)-23 identifies patients with stable ischemic heart disease (SIHD) at high risk of cardiovascular events independent of clinical factors, renal function, and established cardiovascular biomarkers; and 2) FGF-23 ident...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Udell, Jacob A., Morrow, David A., Jarolim, Petr, Sloan, Sarah, Hoffman, Elaine B., O’Donnell, Thomas F., Vora, Amit N., Omland, Torbjørn, Solomon, Scott D., Pfeffer, Marc A., Braunwald, Eugene, Sabatine, Marc S.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2014
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4213068/
https://ncbi.nlm.nih.gov/pubmed/24727254
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jacc.2014.03.026
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller